Question 1

What is Mazdutide?

Accepted Answer

Mazdutide is a dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly, currently in Phase III clinical trials. It is one of several next-generation obesity drugs competing in the dual/triple agonist space alongside survodutide and retatrutide. Notably, mazdutide uses bi-weekly (every 2 weeks) dosing rather than weekly, which could be a convenience advantage.

Question 2

What are the research benefits of Mazdutide?

Accepted Answer

Research on Mazdutide has investigated its potential effects in several areas, including: Bi-weekly dosing — most convenient dosing schedule in the class; Up to 14.4% weight loss in Phase II (24 weeks); Dual GLP-1/glucagon mechanism targets liver fat; Advanced in Chinese regulatory pathway. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does Mazdutide work?

Accepted Answer

Mazdutide activates both GLP-1 and glucagon receptors, similar to survodutide. The GLP-1 component suppresses appetite and improves glucose metabolism, while glucagon receptor activation increases energy expenditure and hepatic fat oxidation. The bi-weekly dosing is achieved through a modified Fc-fusion structure that extends the half-life beyond typical weekly GLP-1 agonists.

Question 4

What is the FDA/legal status of Mazdutide?

Accepted Answer

Mazdutide is currently in clinical trials and is not yet FDA-approved for general use. It may only be used in the context of approved clinical trial protocols. It is not available for general consumer purchase in the United States.

Question 5

What are the known risks or side effects of Mazdutide?

Accepted Answer

Based on available research, Mazdutide has been associated with the following in study settings: GI side effects (nausea, diarrhea, vomiting) — class effect; Decreased appetite; Injection site reactions; Full safety profile not yet established. Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on Mazdutide?

Accepted Answer

Published research on Mazdutide can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "Mazdutide" or its aliases (IBI362, LY3305677) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

Mazdutide

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

Obesity in China: current progress and future prospects.

IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

Mazdutide: First Approval.

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer